CAJ | 학술논문

三阴性乳腺癌是指雌激素受体（estrogen receptor，ER）、孕激素受体（progesterone receptor，PR）及人类表皮生长因子受体-2（human epidermal growth factor receptor-2，HER-2）均为阴性的乳腺癌。三阴性乳腺癌患者因不具备内分泌治疗和抗HER-2治疗的靶点，因此在治疗方面以化疗为主。贝伐珠单抗作为一种针对人血管内皮生长因子（vascular endothelial growth factor， VEGF）的单克隆抗体，在三阴性乳腺癌中是仅有的使用比较广泛的靶向治疗药物。本文将就贝伐珠单抗在三阴性乳腺癌的新辅助治疗、辅助治疗和晚期一线、二线治疗方面的相关研究进行综述。
삼음성유선암시지자격소수체（estrogen receptor，ER）、잉격소수체（progesterone receptor，PR）급인류표피생장인자수체-2（human epidermal growth factor receptor-2，HER-2）균위음성적유선암。삼음성유선암환자인불구비내분비치료화항HER-2치료적파점，인차재치료방면이화료위주。패벌주단항작위일충침대인혈관내피생장인자（vascular endothelial growth factor， VEGF）적단극륭항체，재삼음성유선암중시부유적사용비교엄범적파향치료약물。본문장취패벌주단항재삼음성유선암적신보조치료、보조치료화만기일선、이선치료방면적상관연구진행종술。
The characteristic of triple-negative breast cancer (TNBC) is defined as ER-negative, PgR-negative, and HER2-nega-tive. Chemotherapy is primarily used to treat TNBC because TNBC patients do not have the targets of endocrine therapy and HER-2 therapy. Bevacizumab is the only widely used target drug in TNBC and acts as a monoclonal antibody target on human vascular endo-thelial growth factor. This article provides a review on the progress of using bevacizumab in neo-adjuvant therapy, adjuvant therapy, and first-and second-line treatment of TNBC.